Media Release
- Synaffix to provide
access to proprietary antibody-drug conjugate
(ADC)
technologies
- Genmab secures rights
for conducting research on ADCs against multiple
drug targets with options for exclusive
worldwide development and
commercialization of resulting
therapies
- Synaffix to receive an upfront payment
of USD $4.5 million with a total deal
value of up to
USD $415 million plus tiered single digit
royalties on sales of successfully commercialized
therapies
COPENHAGEN, Denmark and
AMSTERDAM,
Netherlands; 4
January,
2022 —
Genmab A/S (Nasdaq: GMAB) and Synaffix B.V.,
announced today that Genmab and Synaffix have signed a license
agreement providing Genmab broad access to Synaffix’s ADC
technologies. Genmab is granted exclusive research rights to
utilize Synaffix ADC technologies for one drug target with the
option for the worldwide development and commercialization of the
resulting ADCs. Genmab has the option to exercise exclusive
research and commercial licenses for additional targets.
For each specific target nominated under the
license agreement, Genmab gains exclusive access to Synaffix’s
clinical-stage GlycoConnect™ antibody conjugation technology,
HydraSpace™ polar spacer technology, as well as select toxSYN™
linker-payloads, each designed to enable ADCs with best-in-class
efficacy and tolerability for the development of multiple potential
therapies.
Genmab will be responsible for the research,
development, manufacturing and commercialization of any resulting
ADC therapies. At the same time, Synaffix will support Genmab’s
research activities, including manufacturing of components that are
specifically related to its proprietary ADC technologies.
“At Genmab, we are committed to bringing
differentiated medicines to patients, and we believe collaborations
are foundational to accelerate innovation,” said Jan van de Winkel,
Ph.D., Chief Executive Officer, Genmab. “We look forward to working
with Synaffix toward our shared goal of developing best-in-class or
first-in-class antibody therapies and make an impact on the lives
of patients.”
“In what represents our fifth out-licensing deal
in the last six months, we are thrilled to partner with Genmab, an
international biotechnology company,” said Peter van de Sande,
Chief Executive Officer of Synaffix. “In deploying our cutting-edge
ADC technology platform together with Genmab’s robust antibody
development capabilities, Synaffix is privileged to once more play
an essential role in strengthening a partner’s pipeline with our
innovative ADC technologies thereby aiding the transformation of
cancer treatment.”
Financial TermsUnder the terms
of the agreement, Synaffix will receive an upfront payment of USD
$4.5 million and, on a target-by-target basis, is eligible to
receive option-exercise, development-, regulatory- and commercial
milestone payments. The total potential deal value is USD $415
million plus tiered, mid-single digit royalties on commercial
sales.
About Genmab Genmab is an international
biotechnology company with a core purpose to improve the lives of
people with cancer. For more than 20 years, Genmab’s vision to
transform cancer treatment has driven its passionate, innovative
and collaborative teams to invent next-generation antibody
technology platforms and leverage translational research and data
sciences, fueling multiple differentiated cancer treatments that
make an impact on people’s lives. To develop and deliver novel
therapies to patients, Genmab has formed 20+ strategic partnerships
with biotechnology and pharmaceutical companies. Genmab’s
proprietary pipeline includes bispecific T-cell engagers,
next-generation immune checkpoint modulators, effector function
enhanced antibodies and antibody-drug conjugates.
Genmab is headquartered in Copenhagen, Denmark with
locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S.
and Tokyo, Japan. For more information, please visit Genmab.com and
follow us on Twitter.com/Genmab.
About Synaffix B.V.Synaffix
B.V. is a biotechnology company that enables ADC product candidates
using its clinical-stage, site-specific ADC technology platform. In
addition to GlycoConnect™ and HydraSpace™ technology, the toxSYN™
linker-payload platform rounds out a fully complementary technology
platform that enables any company with an antibody to develop
proprietary best-in-class ADC products under a single license from
Synaffix.
The Synaffix platform enables a rapid timeline
to clinic due to the established supply chain of technology
components. Granted patents covering Synaffix’ technology provide
end-to-end protection of the manufacturing technology as well as
the resulting products through at least 2035. The business model of
Synaffix is target-specific technology out-licensing, as
exemplified through its existing deals with ADC Therapeutics,
Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics,
ProfoundBio and Kyowa Kirin.
Synaffix is backed by a top tier, life
science-focused investor syndicate that includes Aravis,
BioGeneration Ventures, BOM Capital and M Ventures.
For more information, please visit the website
at www.synaffix.com.
Contact:
Genmab Marisol
Peron, Senior Vice President, Global Investor Relations &
CommunicationsT: +1 609 524 0065; E: mmp@genmab.com
Investor Relations: Andrew Carlsen, Vice President, Head of
Investor RelationsT: +45 3377 9558; E: acn@genmab.com
Synaffix B.V.Anthony DeBoerVice President,
Business Developmentbd@synaffix.com
Optimum Strategic
CommunicationsHollie Vile, Stella Lempidaki, Vici Rabbetts
+44 (0) 208 078 4357Synaffix@optimumcomms.com This Media Release
contains forward looking statements. The words “believe”, “expect”,
“anticipate”, “intend” and “plan” and similar expressions identify
forward looking statements. Actual results or performance may
differ materially from any future results or performance expressed
or implied by such statements. The important factors that could
cause our actual results or performance to differ materially
include, among others, risks associated with pre-clinical and
clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety
issues, uncertainties related to product manufacturing, the lack of
market acceptance of our products, our inability to manage growth,
the competitive environment in relation to our business area and
markets, our inability to attract and retain suitably qualified
personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated
entities, changes and developments in technology which may render
our products or technologies obsolete, and other factors. For a
further discussion of these risks, please refer to the risk
management sections in Genmab’s most recent financial reports,
which are available on www.genmab.com and the risk factors included
in Genmab’s most recent Annual Report on Form 20-F and other
filings with the U.S. Securities and Exchange Commission (SEC),
which are available at www.sec.gov. Genmab does not undertake any
obligation to update or revise forward looking statements in this
Media Release nor to confirm such statements to reflect subsequent
events or circumstances after the date made or in relation to
actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks:
Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the
Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination
with the DuoBody logo®; HexaBody®; HexaBody in combination with the
HexaBody logo®; DuoHexaBody® and HexElect®.
Media Release no. i02CVR no. 2102 3884LEI Code
529900MTJPDPE4MHJ122
Genmab A/SKalvebod Brygge 431560 Copenhagen VDenmark
- 010422_MR_i02_Genmab and Synaffix
Genesis Healthcare (NYSE:GEN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Genesis Healthcare (NYSE:GEN)
Historical Stock Chart
From Oct 2023 to Oct 2024